Condition: Breast Cancer · Advanced Breast Cancer · Metastatic Breast Cancer · Sponsor: Olema Pharmaceuticals, Inc.
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
This description comes directly from the study's public registry record.
Olema Pharmaceuticals, Inc. · 415-651-7206 · OPERA-01@olema.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Tucson, Arizona, United States | Recruiting |
| Clinical Trial Site | Fountain Valley, California, United States | Not Yet Recruiting |
| Clinical Trial Site | Glendale, California, United States | Not Yet Recruiting |
| Clinical Trial Site | La Jolla, California, United States | Completed |
| Clinical Trial Site | Los Alamitos, California, United States | Recruiting |
| Clinical Trial Site | Los Angeles, California, United States | Recruiting |
| Clinical Trial Site | Whittier, California, United States | Recruiting |
| Clinical Trial Site | Aurora, Colorado, United States | Recruiting |
| Clinical Trial Site | Denver, Colorado, United States | Recruiting |
| Clinical Trial Site | Golden, Colorado, United States | Recruiting |
| Clinical Trial Site | Grand Junction, Colorado, United States | Active Not Recruiting |
| Clinical Trial Site | Danbury, Connecticut, United States | Recruiting |
+ 221 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016738